Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

benzinga.com/analyst-stock-ratings/analyst-color/25/08/47069082/amphastar-secures-fda-nod-for-iron-sucrose-injection-analysts-eye-major-sales

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002.
Iron…

This story appeared on benzinga.com, 2025-08-12 17:38:58.
The Entire Business World on a Single Page. Free to Use →